webinar register page

Medexus (TSX: MDP,OTCQX: MEDXF) Investor Update

Please join Dr. Filippo Milano, M.D., Ph.D. today at 4pm ET to discuss the results of Treosulfan’s Pivotal Study. The study’s primary endpoint and key secondary endpoints were met and found event-free survival and overall survival superior after treosulfan compared to RIC busulfan, also found non-relapse mortality lower in treosulfan arm than busulfan arm. The study results are accepted for publication with American Journal of Hematology and are now available online.

Dr. Filippo Milano is a physician-scientist whose research is focused on the use of umbilical cord blood as a source of stem cells for transplantation to treat blood cancers. He is an Associate Professor in the Clinical Research Division at Fred Hutch and also a Director, of the Cord Blood Transplant Program sted Transplantation in the Clinical Research Division at Fred Hutch.

Please see full Bio here: https://www.fredhutch.org/en/faculty-lab-directory/milano-filippo.html

Jun 6, 2022 04:00 PM in Eastern Time (US and Canada)